NCT01523821View on ClinicalTrials.gov

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 11, 2013

Primary Completion Date

January 15, 2017

Study Completion Date

January 15, 2017

Conditions
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Interventions
DRUG

Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]

Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01523821 - Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) | Biotech Hunter | Biotech Hunter